Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria, 1090
Location status: Recruiting
NCT Number: NCT03401879
Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men. MS is traditionally diagnosed by the presentation of lesions of the central nervous system, disseminated in time and in space, proven by clinical examination and magnetic resonance imaging. Several anatomical parameters in the eye, both vascular and neural, have been found to be altered in MS patients.
Because of its unique optical properties, the eye offers the possibility of the non-invasive assessment of both structural and functional alterations in neuronal tissue. As the neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative changes in the brain are accompanied by structural and possibly also functional changes in the neuro-retina and the ocular vasculature.
The current study seeks to test the hypothesis that beside the known anatomical changes, also functional changes can be detected in the retina of patients with MS. For this purpose, flicker light induced hyperemia will be measured in the retina as a functional test to assess the coupling between neural activity and blood flow. Further, structural parameters such as retinal nerve fiber layer thickness and function parameters such as ocular blood flow and retinal oxygenation will be assessed and compared to age and sex matched controls.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Vienna, Austria, 1090
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for healthy subjects:
Inclusion criteria
for patients with MS:
Any of the following will exclude a healthy subject from the study:
Any of the following will exclude a patient from the study:
Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
Retinal blood flow will be assessed using FDOCT.
Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
Retinal microvasculature will be assessed using OCTA.
Time frame: 1 day
Response of retinal blood flow to flicker light assessed with FDOCT
Time frame: 1 day
Response of retinal vessel diameters to flicker light assessed with DVA
Time frame: 1 day
Retinal oxygen saturation measured with DVA
Time frame: 1 day
Retinal nerve fiber layer thickness measured using OCT
Time frame: 1 day
Retinal layer specific blood flow signal measured using OCTA
Contact information is provided by the study sponsor or research team.
Medical University of Vienna
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06389968
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Munich, Bavaria, Germany
View Trial DetailsNCT05359653
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
San Francisco, California, United States
View Trial DetailsNCT06408259
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Loma Linda, California, United States
View Trial DetailsNCT06390930
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial Details